Pyrethroids as Promising Marine Antifoulants: Laboratory and Field Studies

Due to the regulations and bans regarding the use of traditional toxic chemicals against marine fouling organisms and the practical impediments to the commercialization of natural product antifoulants, there is an urgent need for compounds that are antifouling-active, environmentally friendly, and have a potential for commercial application. In this study, a series of common, commercially available pyrethroid products, which are generally used as environmentally safe insecticides, was evaluated for antifouling activity in the laboratory using an anti-settlement test with cyprids of the barnacle Balanus albicostatus and also in a field experiment. Laboratory assay showed that all eleven pyrethroids (namely, rich d-trans-allethrin, Es-biothrin, rich d-prallethrin, S-prallethrin, tetramethrin, rich d-tetramethrin, phenothrin, cyphenothrin, permethrin, cypermethrin, and high active cypermethrin) were able to inhibit barnacle settlement (EC₅₀ range of 0.0316 to 87.00 μg/ml) without significant toxicity. Analysis of structure–activity relationships suggested that the cyano group at the α-carbon position had a significant influence on the expression of antifouling activity in pyrethroids. In the field, the antifouling activity of pyrethroids was further confirmed, with the most potent pyrethroids being cypermethrin and high active cypermethrin, which displayed efficiency comparable with that of tributyltin. In summary, our investigation indicated that these pyrethroids have a great and practical commercial potential as antifouling agents.     

Insect Biocontrol with Non-endemic Entomopathogenic Nematodes (Steinernema and Heterorhabditis spp.): Conclusions and Recommendations of a Combined OECD and COST Workshop on Scientific and Regulatory Policy Issues

Fifteen invited experts from 10 Organisation for Economic Cooperation and Development (OECD) and European countries participating in the European Commission's Cooperation in the Field of Science and Technical Research (COST) Action 819, along with 12 other participants, met to review and debate the potential problems associated with the introduction and commercial use of non-indigenous nematodes for insect biological control. The consensus view of the participants was that entomopathogenic nematodes (EPNs) possess specific biological and ecological features, which make their use in biological control exceptionally safe. All the scientific evidence available supports the conclusion that EPNs are safe to the environment, as well as to production and application personnel, the general public and the consumers of agricultural products treated with them. Only a few potential, but very remote, risks could be identified. Therefore, it was recommended that EPNs should not be subject to any kind of registration. The introduction of non-indigenous nematode species, however, should be regulated. Species should be accurately identified, and details of the origin, known distribution, probable host range and safety to the user must be provided. In addition, an expert opinion, based on available information, of the possible impact on non-target organisms must be available.     

Natural products as antifouling compounds: recent progress and future perspectives

Since early 2008, an increasing number of countries have ratified an international treaty to ban the application of antifouling (AF) coatings based on organotin compounds (eg tributyltin (TBT) and triphenyltin). As a result, the demand for environmentally friendly, non-toxic or low-toxicity AF compounds and technologies (green AF agents) has become an urgent reality. Marine coatings based on Cu₂O and various other biocides have a negative impact on the environment and they must eventually be replaced by new, effective, and environmentally friendly AF compounds. This mini-review describes important AF compounds discovered from a variety of organisms from 2004 until mid 2009, and discusses recent and general trends in the discovery of AF compounds. Finally, a perspective on the future of AF compound development is presented. The discussion is aimed at updating scientists and engineers on the current challenges facing AF research.     

Preclinical safety testing of biotechnology-derived pharmaceuticals

The unique and complex nature of biotechnology-derived pharmaceuticals has meant that it is often not possible to follow the conventional safety testing programs used for chemicals, and hence they are evaluated on a case-by-case basis. Nonclinical safety testing programs must be rationally designed with a strong scientific understanding of the product, including its method of manufacture, purity, sequence, structure, species specificity, pharmacological and immunological effects, and intended clinical use. This knowledge, coupled with a firm understanding of the regulatory requirements for particular product types, will ensure that the most sensitive and regulatory-compliant test systems are used to optimize the chances of gaining regulatory approval for clinical testing or marketing authorization in the shortest possible time frame.     

Disease Surveillance Strategies in Swine

Preparations derived from plants were the original therapeutic interventions used by man to control diseases (including parasites), both within humans and livestock. Development of herbal products depended upon local botanical flora with the result that different remedies tended to develop in different parts of the world. Nevertheless, in some instances, the same or related plants were used over wide geographic regions, which also was the result of communication and/or the importation of plant material of high repute. Thus, the Nordic countries have an ancient, rich and diverse history of plant derived anthelmintic medications for human and animal use. Although some of the more commonly used herbal de-wormers were derived from imported plants, or their products, many are from endemic plants or those that thrive in the Scandinavian environment. With the advent of the modern chemotherapeutic era, and the discovery, development and marketing of a seemingly unlimited variety of highly efficacious, safe synthetic chemicals with very wide spectra of activities, herbal remedies virtually disappeared from the consciousness – at least in the Western world. This attitude is now rapidly changing. There is a widespread resurgence in natural product medication, driven by major threats posed by multi-resistant pest, or disease, organisms and the diminishing public perceptions that synthetic chemicals are the panacea to health and disease control. This review attempts to provide a comprehensive account of the depth of historical Nordic information available on herbal de-wormers, with emphasis on livestock and to provide some insights on potentially rewarding areas of "re-discovery" and scientific evaluation in this field.     

Regulatory considerations for marker vaccines and diagnostic tests in the U.S.

Marker vaccines and diagnostic tests can prove to be invaluable in disease eradication and control programs, as was found in the pseudorabies (Aujeszky's Disease) virus eradication program in the U.S. During that campaign, numerous gene-deleted vaccines and companion diagnostic test kits were used to differentiate infected animals from vaccinated animals, in a strategy that ultimately led to eradication of the disease in commercial swine herds. The United States Department of Agriculture played a key role in delivery of that success by developing biologics policy, evaluating each product, and ensuring that the conditions of licensure were met. What was most critical in the overall eradication effort, however, was the detailed and dedicated interaction among key players: the biologics regulators, manufacturers, Federal, State, and local regulatory partners, veterinary researchers, industry associations, and animal owners. A good disease control program has to include all of these. The regulatory requirements for licensure of marker vaccines and diagnostic test kits are not different from that for other products. There are several mechanisms for vaccine approval, some more rapid than others, but only a few that could apply to these products. Generally, the platforms that might support marker vaccines and companion diagnostic kits are those based on genetic engineering or protein manipulation. If the product is derived from the application of biotechnology, then additional regulatory considerations are applicable. Most important of these are the considerations found in the National Environmental Policy Act (NEPA), wherein deliberate release of any organism containing recombinant DNA into the environment is subject to review and approval by appropriate federal agencies. Environmental release and NEPA compliance are discussed.     

Challenges in constructing statistically based structure-activity relationship models for developmental toxicity

Regulatory agencies are increasingly called upon to review large numbers of environmental contaminants that have not been characterized for their potential to pose a health risk. Additionally, there is special interest in protecting potentially sensitive subpopulations and identifying developmental toxicants that may be present in the environment. Thus, there is an urgent need for efficient methods to screen large numbers of chemicals for their potential to pose a developmental hazard. One potential screening method involves the use of statistically based structure-activity relationship (SAR) tools to predict activity of untested chemicals. Such systems rely on statistical analyses to discern relationships between structure and activity for a training set of substances. Predictions can then be made for an untested substance as long as its structural features are encompassed by chemicals of the training set. In theory, such systems could assist regulatory agencies in their screening efforts; however, to date, there has been little independent evaluation of these tools for this use. To contribute to such an evaluation, the International Life Sciences Institute Risk Science Institute (ILSI RSI) convened a Working Group to examine methodology used to construct statistically based SAR systems for developmental toxicity. This document reports on the deliberations of the Working Group, which concluded that an improved process is needed for utilizing developmental toxicity data in the construction of statistically based SAR models. The process must be objective, reproducible, rational and transparent. Moreover, it must be informed by the expertise of developmental toxicologists and biologists and must be subject to peer review.     

Principles of Biofouling Protection in Marine Sponges: A Model for the Design of Novel Biomimetic and Bio-inspired Coatings in the Marine Environment?

The process of biofouling of marine structures and substrates, such as platforms or ship hulls, proceeds in multiple steps. Soon after the formation of an initial conditioning film, formed via the adsorption of organic particles to natural or man-made substrates, a population of different bacterial taxa associates under the formation of a biofilm. These microorganisms communicate through a complex quorum sensing network. Macro-foulers, e.g., barnacles, then settle and form a fouling layer on the marine surfaces, a process that globally has severe impacts both on the economy and on the environment. Since the ban of tributyltin, an efficient replacement of this antifouling compound by next-generation antifouling coatings that are environmentally more acceptable and also showing longer half-lives has not yet been developed. The sponges, as sessile filter-feeder animals, have evolved antifouling strategies to protect themselves against micro- and subsequent macro-biofouling processes. Experimental data are summarized and suggest that coating of the sponge surface with bio-silica contributes to the inhibition of the formation of a conditioning film. A direct adsorption of the surfaces by microorganisms can be impaired through poisoning the organisms with direct-acting secondary metabolites or toxic peptides. In addition, first, compounds from sponges have been identified that interfere with the anti-quorum sensing network. Sponge secondary metabolites acting selectively on diatom colonization have not yet been identified. Finally, it is outlined that direct-acting secondary metabolites inhibiting the growth of macro-fouling animals and those that poison the multidrug resistance pump are available. It is concluded that rational screening programs for inhibitors of the complex and dynamic problem of biofilm production, based on multidisciplinary studies and using sponges as a model, are required in the future.     

mAbs: A business perspective

The twenty two monoclonal antibodies (mAbs) currently marketed in the U.S. have captured almost half of the top-20 U.S. therapeutic biotechnology sales for 2007. Eight of these products have annual sales each of more than $1 B, were developed in the relatively short average period of six years, qualified for FDA programs designed to accelerate drug approval, and their cost has been reimbursed liberally by payers. With growth of the product class driven primarily by advancements in protein engineering and the low probability of generic threats, mAbs are now the largest class of biological therapies under development. The high cost of these drugs and the lack of generic competition conflict with a financially stressed health system, setting reimbursement by payers as the major limiting factor to growth. Advances in mAb engineering are likely to result in more effective mAb drugs and an expansion of the therapeutic indications covered by the class. The parallel development of biomarkers for identifying the patient subpopulations most likely to respond to treatment may lead to a more cost-effective use of these drugs. To achieve the success of the current top-tier mAbs, companies developing new mAb products must adapt to a significantly more challenging commercial environment.Key words: autoimmune, biosimilars, buy and bill, comparative trials, drug approval, monoclonal, oncology, reimbursement     

Marine microbial natural products in antifouling coatings

Ecological problems associated with current antifouling technologies have increased interest in the natural strategies that marine organisms use to keep their surfaces clean and free from fouling. Bacteria isolated from living surfaces in the marine environment have been shown to produce chemicals that are potential antifoulants. Active compounds from the cells and culture supernatant of two bacterial strains, FS‐55 and NudMB50–11, isolated from surface of the seaweed, Fucus serratus, and the nudibranch, Archidoris pseudoargus, respectively, were extracted using solid phase extraction. The extracts were combined with acrylic base paint resin and assayed for antifouling activity by measuring their ability to inhibit the growth of fouling bacteria. These formulations were found to be active against fouling bacteria isolated from marine surfaces. The formulation of antifouling paints that incorporate marine microbial natural products is reported here for the first time. This is a significant advance towards the production of an environmentally friendly antifouling paint that utilises a sustainable supply of natural biodegradable compounds.     

Tributyltin-induced imposex in stenoglossan gastropods: Pathological effects on the female reproductive system

• 1.1. The imposition of male sex organs on female stenoglossan gastropods—“imposex”—is a worldwide phenomenon now known to be associated with the usage of marine antifouling paints containing tributyltin (TBT) compounds.
• 2.2. The effect of the imposex response on the female reproductive system varies according to species: in some, breeding appears unaffected, whilst in others the anatomy of the oviduct may be so modified that the female is effectively sterilised.
• 3.3. New evidence suggests that TBT interrupts steroid metabolism, notably the conversion of testosterone to oestradiol 17β.

     

New preparations comprising recombinant human growth hormone: deliberations on the issue of biosimilars

Manufactured recombinant human GH (rhGH) has been available for more than 25 years. In the meantime, the GH produced by various manufacturers has been approved for application in replacement therapy in children and adults with GH deficiency or a number of disorders involving small stature in children. Until recently approval for each individual diagnosis was only granted after extensive studies on the long-term efficacy (e.g. adult height reached) and safety of the various products. Meanwhile, the European approving agency, the European Medicines Evaluation Agency (EMEA), has relinquished this restrictive stance. Thus, new rhGH preparations can count on gaining approval for existing indications even without conducting standard clinical studies of their efficacy and safety for each of these indications. The EMEA's reconsideration is apparently based on the rationale that recombinant GH can, in effect, be considered equivalent to the tried and tested preparations in wide use, provided certain specifications are met. The term 'biosimilars' was coined to denote the similarities between the products rather than their parity, as is the case with generics for instance. The higher complexity of biopharmaceuticals relates not only to the substances themselves but also to the manufacturing process. It is generally believed that modifications to a manufacturing process - which are a prerequisite for a patent - may cause modifications of the active substance which then may lead to different long-term effects. Thus, the term 'biosimilar' does not indicate that complex biopharmaceuticals deriving from the same substance are entirely identical, nor does the approval of a 'biosimilar' ensure this. The factual information provided here is offered towards clarification of some uncertainties and as a contribution towards resolving open questions relating to the topic of biosimilars. The final choice of product to be prescribed must be made by the informed, independent physician.     

有机锡污染与海产腹足类性畸变

综述了海产腹足类性畸变发生的原因和形态变化,并对利用海产腹足类性畸变进行有机锡污染的生物监测,海产腹足类性畸变的生态毒理学等方面的研究进展及我国的研究现状作了详细的介绍。     

FDA and NIST collaboration on standards development activities supporting innovation and translation of regenerative medicine products

The development of standards for the field of regenerative medicine has been noted as a high priority by several road-mapping activities. Additionally, the U.S. Congress recognizes the importance of standards in the 21st Century Cure Act. Standards will help to accelerate and streamline cell and gene therapy product development, ensure the quality and consistency of processes and products, and facilitate their regulatory approval. Although there is general agreement for the need of additional standards for regenerative medicine products, a shared understanding of standards is required for real progress toward the development of standards to advance regenerative medicine. Here, we describe the roles of standards in regenerative medicine as well as the process for standards development and the interactions of different entities in the standards development process. Highlighted are recent coordinated efforts between the U.S. Food and Drug Administration and the National Institute of Standards and Technology to facilitate standards development and foster science that underpins standards development.     

桶形芋螺和菖蒲芋螺的性畸变

2 0 0 1年 9月和 2 0 0 3年 8月在广东湛江的硇洲岛和 2 0 0 3年 6月在广东阳江的闸坡渔港采集桶形芋螺 (Conus betulinus)和菖蒲芋螺 (Conus vexillum) ,发现两个海区的芋螺雌性个体均发生性畸变 ,性畸变率均为 10 0 % ,但雌 /雄性比仍大于 1.0。两种芋螺的畸变阶段和类型多 ,桶形芋螺有 S3b、S3c、 S4 、S*4 、S5b、S5c,而菖蒲芋螺有 S1 c、S3b、S4 、S*4 、S6 b。 2 0 0 3年 6月在阳江采集的桶形芋螺畸变程度最高 ,种群 RPSI为 5 3.8% ,VDSI高达 4 .9,雌性不育率达 4 4 .0 %。 2 0 0 1年 9月在硇洲岛外海深水区采集的菖蒲芋螺的种群 RPSI虽然只有 14 .7% ,但性畸率为 10 0 % ,VDSI也达 4 .1%。由此可见 ,两种芋螺对有机锡污染均比较敏感 ,而且有个体大、易采集、性畸变率高、畸变阶段跨度大、畸变类型多、畸变特征易于鉴别等特点 ,是中国东南沿海低潮线和潮下带有机锡污染生物监测的理想指示种。如与潮间带有机锡污染指示种疣荔枝螺 (Thaisclavigera)结合起来 ,便可相互补充 ,能更加全面和准确地反映近岸海域有机锡污染的现状     

Impacts of anthropogenic stress on rocky intertidal communities

Rocky shores provide a harsh environment for marine organisms andwe briefly discuss natural sources of variation in community structure beforeconsidering anthropogenic impacts in detail. We review impacts caused by (a) acutedisturbances: oil spills, toxic algal blooms and (b) chronic disturbances: nutrient pollution,oil, heavy metals, pesticides, antifouling paints, collecting, trampling/habitatdegradation, siltation and introduced species. Community level effects are emphasisedthroughout and illustrative examples are drawn from field-based case studies. Particularattention is given to the lessons learned from oil spills and the effect of chronicpollution by tributyltin on dogwhelks, the impacts of which ranged from the biochemical tocommunity levels of organisation. Impacts are placed in a global and historicalperspective and the potential for the recovery of shores under appropriate management isdiscussed. Finally we consider the relative merits of the multivariate and univariateapproaches to studying impacted communities and suggest priorities for future research.     

Establishing Life Cycle Inventories of Chemicals Based on Differing Data Availability (9 pp)

Goal, Scope and Background In contrast to inventory data of energy and transport processes, public inventory data of chemicals are rather scarce. Chemicals are important to consider in LCA, because they are used in the production of many, if not all, products. Moreover, they may cause considerable environmental impacts. For these reasons, it was one goal of the new ecoinvent database to provide LCI data on chemicals. In this paper, the methods and procedures used for establishing LCIs of chemicals in ecoinvent are presented.Methods Three different approaches are suggested for situations of differing data availability. First, in the case of good data availability, the general quality guidelines of ecoinvent can be followed. Second, a procedure is proposed for the translation of aggregated inventory data (cumulative LCI results) from industry into the ecoinvent format. This approach was used, if adequate unit process data was not available. Third, a procedure is put forward for estimating inventory data using stoichiometric equations from technical literature as a main information source. This latter method was used if no other information was available. The application of each of the three procedures is illustrated with the help of a case study.Results and Conclusion When sufficient information is available to follow the general guidelines of ecoinvent, the resulting dataset is characterized by a high degree of detail, and it is thus of high quality. For chemicals, however, the application of the standard procedure is possible in only a few cases. When using industrial data, the main drawback is the fact that those data are often available only as aggregated data, thus being out of tune with the quality guidelines of ecoinvent and its main aim, the harmonization of LCI data. As a third approach, the use of the stoichiometric reaction equation is used for the compilation of LCI datasets of chemicals. This approach represents an alternative to neglecting chemicals completely, but it contains a high risk to not consider important aspects of the life cycle of the respective substance.Outlook Further work in the area of chemicals should focus on an improvement of datasets, so far established by either of the two estimation procedures (APME method; estimation based on technical literature) described. Besides the improvement of already established inventories, the compilation of further harmonized inventories of specific types of chemicals (e.g. solvents) or of chemicals for new industrial sectors (e.g. electronics industry) are in discussion.     

mAbs

The twenty two monoclonal antibodies (mAbs) currently marketed in the U.S. have captured almost half of the top-20 U.S. therapeutic biotechnology sales for 2007. Eight of these products have annual sales each of more than $1 B, were developed in the relatively short average period of six years, qualified for FDA programs designed to accelerate drug approval, and their cost has been reimbursed liberally by payers. With growth of the product class driven primarily by advancements in protein engineering and the low probability of generic threats, mAbs are now the largest class of biological therapies under development. The high cost of these drugs and the lack of generic competition conflict with a financially stressed health system, setting reimbursement by payers as the major limiting factor to growth. Advances in mAb engineering are likely to result in more effective mAb drugs and an expansion of the therapeutic indications covered by the class. The parallel development of biomarkers for identifying the patient subpopulations most likely to respond to treatment may lead to a more cost-effective use of these drugs. To achieve the success of the current top-tier mAbs, companies developing new mAb products must adapt to a significantly more challenging commercial environment.     

Issues in the development of medical products based on human plasma

Product development and process validation are shown in the case of several products obtained from human plasma. These are virus-inactivated plasma, intravenous immunoglobulins and the clotting factors VIII and IX. Different analytical methods are presented, which are used for product control and in-process control. For the production of virus-inactivated human plasma a down-scale protocol is presented, allowing a simulation of the production on a laboratory scale. Virus validation has shown that the reduction of transfusion-relevant viruses in the process was higher than six log steps. Determination of leachables from the RP-column, which was used in this production, proved that they appear in the final product in quantities below the detection limits only. It was also shown that the chemicals used for virus inactivation could be quantitatively removed from the product. For the isolation of other products, here intravenous gamma globulins and the clotting factors VIII and IX, similar validation steps had to be taken. In the case of clotting factor VIII the following data were determined, the reduction of viruses, the amount of leachables from the column, the residues of chemicals from the solvent/detergent treatment for virus inactivation. Virus reduction was successfully performed as well as the removal of chemicals used for virus inactivation. The amount of leachables from the columns used for chromatographic purification was found to be far below the permissible levels.     

Development of a method for the production of hemicellulosic gels from Sitka spruce

Timber can be used as a sustainable source for process chemicals (Silvichemicals), with particular emphasis being placed on wood as source of chemical feedstocks. Bulk Silvichemicals are unlikely to be cost competitive with fossil fuel derived chemicals at present so ideally, research should be directed towards materials with exploitable properties and high intrinsic value in the market place. Research has generally been aimed at the utilisation of cellulose, extractives or degradation products with only minor interest in the utilisation of undegraded hemicelluloses. To increase the intrinsic value the environmental credentials of the product must be considered. The aim of this study was to development a mechanical and/or mild chemical method for the extraction of hemicelluloses in the form of gels. A number of parameters were tested and are detailed and discussed in terms of effectiveness and feasibility. Mechanical refining followed by mild alkaline extraction was found to be effective on a laboratory scale.